Novartis’ severe aplastic anaemia drug fast-tracked by FDA

"The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.

Priority Review designation is used for treatments that address a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in treatment safety or efficacy."

- By Linda Banks,

Read More

back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo